Sarina Tanimoto - Aug 19, 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
CHIEF MEDICAL OFFICER, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Aug 19, 2025
Transactions value $
-$703,755
Form type
4
Date filed
8/21/2025, 05:36 PM
Previous filing
Jan 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tanimoto Sarina CHIEF MEDICAL OFFICER, 10%+ Owner C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO /s/ Kathleen Scott, Attorney-in-Fact 2025-08-21 0001951291

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Sale -$173K -12.3K -0.95% $14.03 1.29M Aug 19, 2025 By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 F1, F2, F3
transaction SPRY Common Stock Sale -$531K -37.7K -2.93% $14.09 1.25M Aug 20, 2025 By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 F1, F3, F4
holding SPRY Common Stock 1.25M Aug 19, 2025 By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 F5
holding SPRY Common Stock 8.86M Aug 19, 2025 By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025.
F2 The weighted average sale price for the transaction reported was $14.0254 and the range of prices were between $14.00 and $14.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The Reporting Person is trustee of the trust.
F4 The weighted average sale price for the transaction reported was $14.0914 and the range of prices were between $14.00 and $14.205. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F6 The number of shares reported is comprised of (i) 1,098,499 shares that were previously reported as indirectly held by the Family Trust, (ii) 3,433,512 shares that were previously reported as directly held by the Reporting Person, and (iii) 4,327,189 shares that were previously reported as indirectly held by the Reporting Person's spouse.
F7 The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.